Adage Capital Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Adage Capital Partners’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,641,012	Closed	-$87.7M	–	1010
2023 Q1	$87.7M	Buy	3,641,012 +1,121,755	+45%	+$14.1M	0.2%	125
2022 Q4	$26.6M	Sell	2,519,257 -3,250,743	-56%	-$26.2M	0.06%	349
2022 Q3	$26M	Buy	5,770,000 +4,870,000	+541%	+$22.2M	0.06%	339
2022 Q2	$3.6M	Buy	900,000 +190,677	+27%	+$904K	0.01%	836
2022 Q1	$5.19M	Buy	+709,323	New	+$4.24M	0.01%	828

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Adage Capital Partners's PRVB Position: Q2 2023 in Review

Adage Capital Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 3,641,012 shares — an estimated $87.7M sold.

Adage Capital Partners first reported a position in PRVB in Q1 2022 and held it in 5 quarters. The position peaked at $87.7M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Adage Capital Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Adage Capital Partners sold 3,641,012 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $87.7M.
Adage Capital Partners first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Adage Capital Partners's Provention Bio, Inc. Common Stock position peaked at $87.7M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.